Lantern Pharma (LTRN) Current Leases (2021 - 2026)
Lantern Pharma's (LTRN) quarterly Current Leases came in at $59076.0 in Q1 2026, little changed YoY from $59076.0 in Q1 2025, and down 24.78% on a QoQ basis from $78539.0 in Q4 2025.
Lantern Pharma (LTRN) Current Leases (2021 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 6 years of Current Leases data on file, last reported at $59076.0 in Q1 2026.
- Quarterly Current Leases changed 0.0% year-over-year to $59076.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59076.0 (changed 0.0% YoY) and the FY2025 annual result came in at $78539.0, down 58.84% from the prior year.
- Current Leases slipped to $59076.0 in Q1 2026, from $78539.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $197291.0 in Q3 2024 to a low of $52890.0 in Q4 2022.
- A 5-year average of $129812.8 and a median of $131515.0 in 2025 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases jumped 227.05% — and 2025, when it plunged 66.82%.
- Tracing LTRN's Current Leases over 5 years: stood at $52890.0 in 2022, then jumped by 227.05% to $172975.0 in 2023, then climbed by 10.31% to $190814.0 in 2024, then plunged by 58.84% to $78539.0 in 2025, then slipped by 24.78% to $59076.0 in 2026.
- The last three Current Leases figures came in at $59076.0 (Q1 2026), $78539.0 (Q4 2025), and $93954.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 59,076.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59,076.00 |
| Dec 31, 2025 | 78,539.00 |
| Sep 30, 2025 | 93,954.00 |
| Jun 30, 2025 | 131,515.00 |
| Mar 31, 2025 | 59,076.00 |
| Dec 31, 2024 | 190,814.00 |
| Sep 30, 2024 | 197,291.00 |
| Jun 30, 2024 | 164,002.00 |
| Mar 31, 2024 | 178,023.00 |
| Dec 31, 2023 | 172,975.00 |
| Sep 30, 2023 | 168,013.00 |
| Jun 30, 2023 | 163,146.00 |
| Mar 31, 2023 | 119,584.00 |
| Dec 31, 2022 | 52,890.00 |
| Sep 30, 2022 | 92,023.00 |
| Jun 30, 2022 | 130,705.00 |
| Mar 31, 2022 | 155,192.00 |
| Dec 31, 2021 | 152,058.00 |
| Sep 30, 2021 | 148,960.00 |
| Jun 30, 2021 | 145,898.00 |